| Currently Enrolling for: |
Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of PSVT
The primary objective of this study is to evaluate the safety of etripamil nasal spray (NS) 70 mg when self-administered by patients with an episode of Paroxysmal Supraventricular Tachycardia in an outpatient setting (i.e., without medical supervision).
Eligibility Criteria:
| Sex/Gender |
|
|---|
| Ages | 18 Years and older (Adult, Older Adult) |
|---|
| Accepts Healthy Volunteers | No |
|---|
Qualified participants may receive: |
|
Study-related medication at no cost |
|
Study-related medical exams at no cost |
|
No insurance is needed to participate. |
|
If you are interested in participating in our study, please fill out the form below or call us at (919) 267-5209.
Enroll Now: